Prognostic value of PD‐L1 and PD ‐1 expression in upper tract urothelial carcinoma patients

• Published in: BJU international 2023-07
• Main Authors: Campedel, Luca, Compérat, Eva, Cancel-Tassin, Géraldine, Varinot, Justine, Pfister, Christian, Delcourt, Clara, Gobet, Françoise, Roumiguié, Mathieu, Patard, Pierre‐marie, Daniel, Gwendoline, Bigot, Pierre, Carrouget, Julie, Eymerit, Caroline, Larré, Stéphane, Léon, Priscilla, Durlach, Anne, Ruffion, Alain, de Mazancourt, Emilien Seizilles, Decaussin-Petrucci, Myriam, Bessède, Thomas, Lebacle, Cédric, Ferlicot, Sophie, Robert, Grégoire, Vuong, Nam‐son, Philip, Magali, Crouzet, Sébastien, Matillon, Xavier, Mège-Lechevallier, Florence, Lang, Hervé, Mouracade, Pascal, Lindner, Véronique, Gougis, Paul, Cussenot, Olivier, Rouprêt, Morgan, Seisen, Thomas
• Format: Article
• Language: English
• Subjects: Life Sciences
• ISSN: 1464-4096; 1464-410X
• DOI: 10.1111/bju.16129

Objective: To evaluate the prognostic value of PD-L1 and PD-1 expression in upper tract urothelial carcinoma (UTUC) patients.Materials and methods: A retrospective multicenter study was conducted in 283 UTUC patients treated with radical nephroureterectomy (RNU) between 2000 and 2015 at 10 French hospitals. Immunohistochemistry analyses were performed using 2 mm-core tissue micro-arrays with NAT105® and 28.8® antibodies at a 5% cut-off for positivity on tumor cells and tumor-infiltrating lymphocytes to evaluate PD-L1 and PD-1 expression, respectively. Multivariable Cox regression models were used to determine the independent predictors of recurrence-free (RFS), cancer-specific (CSS) and overall survival (OS). Results: Overall, 63 (22.3%) and 220 (77.7%) UTUC patients had PD-L1 positive and negative disease, respectively, while 91 (32.2%) and 192 (67.8%) had PD-1 positive and negative disease, respectively. Patients who expressed PD-L1 or PD-1 were more likely to have ≥pT2(68.3% vs. 49.5%;p=0.009 and 69.2% vs. 46.4%;p